Karyopharm to Present at SVB Securities Global Biopharma Conference
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced participation in the virtual SVB Securities Global Biopharma Conference on February 16, 2023, at 11:20 a.m. ET. The senior management team will engage in a fireside chat, with a live webcast available for replay on the company's website for 90 days post-event. Karyopharm specializes in novel cancer therapies and is known for its lead compound, XPOVIO® (selinexor), which addresses nuclear export dysregulation in oncogenesis. The company also has a diverse pipeline targeting high unmet cancer needs in multiple myeloma, endometrial cancer, and more. For further details, visit www.karyopharm.com.
- None.
- None.
A live webcast of the fireside chat, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 90 days following the event.
About
XPOVIO® and NEXPOVIO® are registered trademarks of
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-present-at-svb-securities-global-biopharma-conference-301742276.html
SOURCE
FAQ
What date and time is Karyopharm presenting at the SVB Securities Global Biopharma Conference?
How can I access the Karyopharm presentation from the SVB Conference?
What is Karyopharm's lead product?